Myasthenia gravis is not inherited in the traditional sense. The vast majority of cases occur in people with no family history of the condition, and it does not follow a predictable inheritance pattern like some genetic diseases do. However, certain genes can increase susceptibility, and having a close relative with myasthenia gravis does raise your risk compared to the general population. About 3 to 5 percent of people with myasthenia gravis have a family member with the same condition or another autoimmune disorder.
Genetic Susceptibility, Not Direct Inheritance
Myasthenia gravis (MG) is an autoimmune disorder, meaning the immune system mistakenly attacks the body’s own tissues. In this case, antibodies target the connection point between nerves and muscles, causing weakness. This is fundamentally different from a condition caused by a single inherited gene mutation. Instead, MG involves a complex web of genetic and environmental factors that together push the immune system toward malfunction.
Several genes involved in immune function have been linked to higher MG risk. The strongest signals come from a family of genes that help the immune system distinguish the body’s own cells from foreign invaders. Specific variations in these genes are associated with different forms of the disease. One variant, for example, is tied to early-onset MG in younger women, while other variants are more common in people who develop MG later in life. A large genome-wide analysis published in Nature Communications confirmed these immune-related genes as the strongest genetic risk factors, while also noting that early-onset and late-onset MG can have opposite genetic associations, meaning a gene variant that raises risk for one type may actually be protective against the other.
Other genes linked to MG susceptibility play roles in inflammation, immune signaling, and how the body regulates its own immune responses. But no single gene causes the disease. Researchers describe it as polygenic, meaning many small genetic contributions add up, and even then, most people carrying those variants never develop MG.
How Much Does Family History Matter?
A population-based study on familial clustering found that having a first-degree relative (parent, sibling, or child) with MG increases your risk roughly 7.8 times compared to people without a family history. That sounds dramatic, but context matters: MG is rare to begin with, affecting roughly 14 to 20 people per 100,000. Among first-degree relatives of MG patients, prevalence was 0.205%, compared to 0.028% in the general population. So even with the elevated risk, your absolute chance remains well under 1 percent.
The risk isn’t evenly distributed across family relationships. Siblings of someone with MG face the highest relative risk, roughly 18 times greater than the general population. For children of an affected parent, the risk is about 6 times higher, and for parents of someone diagnosed, about 5 times higher. These numbers reflect shared genetics and possibly shared environmental exposures, but they reinforce that MG clusters in families only modestly.
Epigenetics and Environmental Triggers
Genes alone don’t tell the full story. Researchers are increasingly finding that epigenetic changes, modifications that turn genes on or off without altering the DNA sequence itself, play an important role in MG. Studies comparing MG patients to healthy individuals have found widespread differences in a chemical tagging system called DNA methylation, which controls how actively certain genes are read by cells. In MG patients, some genes involved in immune regulation and nerve-muscle signaling show abnormal tagging patterns, leading them to be over- or under-expressed.
For example, reduced methylation in the promoter region of acetylcholine receptor genes can increase the production of the very proteins the immune system is attacking. Other genes involved in calcium signaling and stress responses also show altered methylation in MG patients. These epigenetic shifts can be influenced by environmental exposures, infections, stress, and other external factors, which helps explain why someone with a genetic predisposition might develop MG at a particular point in their life while a sibling with similar DNA does not.
Congenital Myasthenic Syndromes Are Different
There is a separate group of conditions called congenital myasthenic syndromes (CMS) that are truly hereditary. These are caused by specific gene mutations that directly disrupt the nerve-muscle connection, and they are present from birth or early childhood. Unlike autoimmune MG, CMS is not caused by antibodies or immune system dysfunction. Most cases involve mutations affecting the postsynaptic membrane, the receiving end of the nerve-muscle junction.
CMS is rare and sometimes misdiagnosed as autoimmune MG, particularly in adults who test negative for the antibodies typically associated with MG. This distinction matters because the treatments are different. Standard MG therapies that suppress the immune system do not help CMS patients and can sometimes make things worse. Neurologists increasingly recommend genetic testing for patients whose antibody tests come back negative, since identifying a CMS mutation can completely change the treatment approach.
Neonatal Myasthenia in Newborns
If you’re a parent with MG wondering about your baby, there’s one more scenario to understand. Mothers with autoimmune MG can temporarily pass their antibodies to the baby through the placenta during pregnancy. This can cause a condition called transient neonatal myasthenia gravis, where the newborn shows muscle weakness, a weak cry, or difficulty feeding in the first days of life. This is not a genetic condition. It resolves on its own, typically within weeks, as the baby’s body naturally clears the mother’s antibodies from its bloodstream. It does not mean the child will develop MG later in life.
Should You Get Genetic Testing?
For most people with autoimmune MG, genetic testing is not part of the standard workup. The diagnosis relies on antibody tests, nerve conduction studies, and clinical evaluation. Genetic testing becomes relevant in a specific situation: when all antibody tests come back negative. Seronegative myasthenia, as it’s called, can sometimes turn out to be a congenital myasthenic syndrome rather than an autoimmune condition. In these cases, next-generation genetic sequencing can identify mutations that point toward CMS, which has direct implications for choosing the right treatment.
If you have a family history of MG and are experiencing symptoms like fluctuating muscle weakness, drooping eyelids, or difficulty swallowing, the first step is the same standard diagnostic pathway anyone would follow. Your family history is worth mentioning to your neurologist, but it won’t change the initial testing. It simply adds context to your overall risk profile.